Homepage
Author:
Mineralys Therapeutics, Inc.
Posted Date:
June 8, 2026
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics, Inc.
June 8, 2026
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics, Inc.
June 8, 2026
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys Therapeutics, Inc.
June 3, 2026
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics, Inc.
June 3, 2026
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics, Inc.
May 30, 2026
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
Mineralys Therapeutics, Inc.
May 27, 2026
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics, Inc.
May 18, 2026
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics, Inc.
May 6, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc.
May 5, 2026
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics, Inc.
May 5, 2026
1
2
Next
